Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

MS Awareness Week – Matt’s story

Matt is 31 and was diagnosed with multiple sclerosis, a chronic immune mediated inflammatory condition, two years ago. Around 100,000 people in the UK are affected by MS and it...

Mednet

Top 10 things to consider when designing hybrid meetings

In this article, we dive into the world of hybrid meetings, including the different definitions of "hybrid," the importance of over-time engagement, and more.

Impetus Digital

Explainer Videos

Explainer Videos in Healthcare Marketing

Could an explainer video help you? Here we’re looking at five reasons to use explainer videos in your healthcare marketing and how they help your content leave a memorable impression.

The Good Ideas Group

- PMLiVE

New study highlights significance of chronic obstructive pulmonary disease flare-ups

COPD causes nearly 30,000 deaths in England each year, with an annual overall cost to the NHS of £1.9bn

- PMLiVE

Pfizer and Valneva announce positive phase 2 paediatric data for lyme disease vaccine

VLA15 is currently the only Lyme disease vaccine candidate in clinical development

the contradiction conundrum report cover

The Contradiction Conundrum: New digital pharma report

New research, based on the views of 450 pharma professionals, reveals contradictions in how pharma organisations are approaching their digital products and strategies.

Graphite Digital

- PMLiVE

Innovative Trials named a finalist in the Inspiring Hertfordshire Awards

The patient recruitment organisation has been shortlisted in the Inspiring Hertfordshire awards

Innovative Trials

- PMLiVE

FDA approves COVID-19 treatment for those under the age of 12

Veklury is currently the only COVID-19 treatment approved for this age group

- PMLiVE

Cancer Research UK drives innovation with Cancer Research Horizons

Industry partners will gain access to an extensive network of 4,000 world-leading cancer researchers

- PMLiVE

Gilead’s Veklury significant decreases risk of hospitalisation for COVID-19 patients

Using Veklury within five days of symptom onset – or between five to seven days of symptom onset – reduced hospitalisations in patients at high risk for severe COVID-19 disease

- PMLiVE

Biogen retracts EMA application for Alzheimer’s drug Aduhelm

The application was pulled after the CHMP said the data provided was not enough to support a marketing authorisation

- PMLiVE

Novartis UK launches local charity partnerships to support social mobility pledges

The company has partnered with the Social Mobility Foundation, Founders4Schools and OnSide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links